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ABSTRACT
Background: Several tumor-suppressor genes, such as 53-kDa protein (p53), 
are inactivated in some pancreatic cancers. The lack of a functional p53 has been pro-
posed to be a component of resistance to chemotherapy, resulting in the inhibition of 
apoptosis. Therefore, reintroduction of wild-type p53 is a commonly used gene thera-
py strategy for the treatment of various types of cancer, including pancreatic cancer.
Objective: The aim of this study was to examine the ability of the histone 
deacetylase inhibitor, sodium butyrate (NaB), to modulate the expression of p53. 
Methods: Five human pancreatic carcinoma cell lines (SW-1990, BxPC-3, 
PANC-1, MIA PaCa-2, JHP-1) were utilized. Two of the cell lines (SW-1990 and 
JHP-1) lacked p53 expression, as determined by Western blot analysis, and were in-
vestigated further. Expression of p53 was determined by densitometry of all bands 
present in the Western blot. Drug sensitivity was measured with a tetrazolium-based 
assay by exposing the cells to graded concentrations of NaB and/or anticancer drugs 
(cisplatin, fluorouracil, SN-38, and paclitaxel). Apoptosis was observed using gel 
electrophoresis.
Results: In the SW-1990 and JHP-1 cell lines, use of 1 mM NaB was found to 
induce histone acetylation and p53 expression compared with those not treated with 
NaB (P = 0.01 and P = 0.018, respectively). Sensitivity to cisplatin (P = 0.021), fluo-
rouracil (P = 0.046), and SN-38 (P = 0.039) was significantly enhanced by NaB 
treatment compared with nontreatment. However, sensitivity to paclitaxel was not 
significantly different between untreated and NaB-treated cells. A higher frequency 
of apoptosis was observed in NaB-treated cells compared with that of control cells.
Conclusion: This in vitro study found that NaB induced p53 expression in 
2 pancreatic cancer cell lines (SW-1990 and JHP-1). Moreover, NaB acted on a bio-
chemical modulator for antieuplastic therapy. Future research is necessary to assess the 
value of these findings. (Curr Ther Res Clin Exp. 2010;71:162–172) © 2010 Excerpta 
Medica Inc.
Key words: sodium butyrate, 53-kDa protein expression, human pancreatic 
carcinoma cell lines, in vitro.
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INTRODUCTION
The prognosis of patients with pancreatic cancer is poor (5-year overall survival rate 
is 2.5%)1 since most cases are in an advanced stage at the time of diagnosis.2 Early 
detection of pancreatic cancer using modern imaging techniques is required for cura-
tive resection.3 Adjuvant chemotherapy is also important for improving the clinical 
outcome.4 Because the effect of anticancer agents is limited, it is important to assess 
and develop new treatments.
53-kDa protein (p53) is a DNA-binding protein and a transcription factor that 
controls the expression of proteins involved in the cell cycle.5,6 In response to DNA 
damage, p53 accumulates in the nucleus causing cells to undergo cell cycle arrest and 
DNA repair or apoptosis.7 Inactivation of p53 can occur by several mechanisms, in-
cluding direct genetic mutation, binding to viral oncoproteins or cellular factors, or 
alteration of its subcellular localization.5,6
The lack of functional p53 has been proposed as a component of resistance to che-
motherapy, resulting in the inhibition of apoptosis.8 Therefore, reintroduction of 
wild-type p53 is a commonly used gene therapeutic strategy for the treatment of vari-
ous types of cancer, including pancreatic cancer.9
Pancreatic cancer represents 80% to 85% of all pancreatic malignancies and is one 
of the most lethal cancers (5-year survival rates after resection range from 10%– 
29%).10–13 In addition to surgery, effective adjuvant therapy is necessary for treating 
pancreatic cancer. Recently, wild-type p53 was shown to induce apoptosis in a murine 
myeloid leukemic cell line14 and a human colonic tumor cell line.15 A therapeutic 
approach that induces overexpression of p53 in malignant pancreatic cells could po-
tentially lead to reconstitution of their ability to undergo apoptosis. A critical determi-
nant of the success of antineoplastic therapy is the ability of malignant cells to undergo 
apoptosis in response to DNA damage caused by radiation or cytotoxic agents. A deficit 
of p53, which is mutated in over 50% of pancreatic cancers, is thought to be a factor 
inhibiting apoptosis.16
Histone deacetylase (HDAC) inhibitors are a new class of antineoplastic agents that 
reactivate tumor suppressor genes, which results in growth inhibition, differentiation, and 
apoptosis of cancer cells.17,18 HDAC inhibitors, including suberoylanilide hydroxamic 
acid, sodium butyrate (NaB), and trichostatin A, have been reported to induce apoptosis. 
NaB has been found to induce apoptosis in monocytic leukemia cells in mice.19
NaB, a 4-carbon fatty acid, is of particular interest because it has been reported to 
inhibit the proliferation of a number of cell types in vitro,20 including colorectal tu-
mor cells.21,22 A previous study found that NaB is cytotoxic to colorectal cells; how-
ever, it is unclear whether this was due to the induction of terminal differentiation or 
to nonspecific toxicity.23 Furthermore, we know that NaB induces several proteins but 
we do not know whether NaB affects p53 induction.24–26 We used NaB, which is an 
HDAC inhibitor that induces an increase in the levels of membranous antigens and 
enzymic activities.27–29 Other HDAC inhibitors are thought to act by promoting 
histone acetylation and, in turn, gene expression.
The p21 gene has been linked to p53 expression and inhibition of cell cycle pro-
gression.30 The importance of p21 as a downstream mediator of tumor suppression 
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was enhanced when it was discovered that p21 was the prototype for a family of small 
cyclin-dependent kinase-inhibiting proteins.
The present study examined the effect of a very low amount (1 mM) of the HDAC 
inhibitor, NaB, on the expression of p53 protein in pancreatic cell lines. It also inves-
tigated whether low doses of NaB lead to increased sensitivity of pancreatic cancer 
cells to anticancer drugs. We also examined the status of p21 in cancer cells after NaB 
treatment.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
Five human pancreatic cancer cell lines were used, SW-1990,31 BxPC-3,32 PANC-1,33
MIA PaCa-2,34 and JHP-1.35 All cell lines were purchased from American Type 
Culture Collection, Manassas, Virginia. SW-1990 cells were maintained at 37°C in 
Leibovitz L-15 medium 10% fetal calf serum. PANC-1 cells were maintained at 37°C 
in Dulbecco’s Modified Eagle’s Medium containing 10% fetal calf serum. BxPC-3, 
MIA PaCa-2, and JHP-1 cells were maintained at 37°C in RPMI-1640 medium con-
taining 10% fetal calf serum.
Protein Isolation and Western Blot Analysis
Cells were scraped into cell lysis buffer containing 10 mM Tris (pH 7.4), 150 mM 
sodium chloride (NaCl), 1% NP40, 1 mM EDTA (TNE), and 20 μg/mL aprotinin. 
Proteins (50 μg) were separated by 7.5% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and electroblotted to a transfer membrane (Immobilon-P, Millipore, 
Billerica, Massachusetts). Nonspecific protein binding was blocked with 5% milk in 
TNE buffer (2 mM Tris [pH 7.4]; 2 mM NaCl; 1 mM EDTA; 0.15% polysorbate 20) 
for 1 hour. The membrane was incubated for 1 hour with a mouse monoclonal anti-
body to p53 and p21 (Santa Cruz Biotechnology, Inc., Santa Cruz, California) and a 
rabbit polyclonal antibody to acetylated histone H3 (Upstate Biotechnology, Lake 
Placid, New York), diluted to 1:1000 in TNE containing 5% milk. Since chromatin 
acetylation increases in cells treated with an HDAC inhibitor, it can be detected using 
an antibody against acetylated chromatin.36 After washing, antimouse or antirabbit 
immunoglobulin horseradish-peroxidase–linked secondary antibody (Amersham 
Pharmacia Biotech Inc., Piscataway, New Jersey) was added for 1 hour. After washing, 
the membrane was developed in Western blotting detection reagents (ECL™, Amer-
sham Pharmacia). The total value of the protein was determined by densitometry of all 
bands present in the Western blot.37 The bands were quantified using a digital scanner 
and NIH Image software version 1.57 (Scion Corp., Frederick, Maryland). p53 expres-
sion was found in BxPC-3, PANC-1, and MIA PaCa-2 cell lines but not in the SW-1990 
and JHP-1 cell lines (Figure 1). The latter 2 cell lines were examined further.
Growth Inhibition and Cell Viability
Cells (3 × 103) were produced in 180 μL of medium per well in 96-well plates in 
triplicate. Drug sensitivity was measured by exposing the cells to graded concentra-
tions which were derived from previous studies38–41 of NaB or anticancer drugs in a 
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final volume of 200 μL. After 72 hours, viable cells were estimated with a colorimetric 
assay that measures the formazan reduction product of MTT (3-[4, 5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide), which is produced by the mitochondrial 
activity of viable cells. The reduced product was dissolved in dimethyl sulfoxide and 
absorbance was measured with a plate-reader spectrophotometer (Bio Rad Benchmark 
Plus, Bio-Rad Laboratories, Inc., Hercules, California).
DNA Fragmentation Analysis
Nucleosomal DNA degradation was analyzed. SW-1990 cells (1 × 105) were seeded 
in 5-cm culture dishes and allowed to adhere overnight. On the next day, fresh me-
dium was added with or without NaB (final concentration 2 mM). After 1 hour of 
incubation at 37°C in 5% carbon dioxide, the medium was aspirated, and fresh me-
dium containing cisplatin (final concentration 0.01, 0.1, or 1 μM) was added. After 
2 days of incubation, cells were harvested and lysed in a solution containing 100 mM 
NaCl, 10 mM Tris (pH 7.4), 25 mM EDTA, and 0.5% sodium dodecyl sulfate. After 
centrifugation, the supernatants were incubated at 65°C for 5 hours with 300 μg/mL 
proteinase K and then extracted with phenol chloroform. The aqueous layer was 
treated with 0.1 volume of 3 M sodium acetate, and the DNA was precipitated with 
2.5 volumes of 95% ethanol. Following treatment with 100 μg/mL RNase A for 
1 hour at 37°C, the sample was electrophoresed on a 2% agarose gel and stained with 
ethidium bromide.
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Figure 1.  Western blot detection of 53-kDa protein (p53). Cell lysates from SW-1990, 
BxPC-3, PANC-1, MIA PaCa-2, and JHP-1 cells were examined by Western blot-
ting with an antibody to p53. Data are the mean of 3 determinations. Error bars 
are 95% CIs. P values are 2-sided (Mann-Whitney U test). ASU = arbitrary 
subunit.
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Statistical Analyses
Differences between groups were tested by ANOVA or Mann-Whitney U test. All 
P values are 2-sided. A 2-sided P < 0.05 was considered to be statistically significant. 
Statistical analyses were conducted using StatView version 4.0 (SAS Institute Inc., 
Cary, North Carolina).
RESULTS
The cytotoxicity of NaB to SW-1990 and JHP-1 cell lines was examined at various 
concentrations of NaB (0.03, 0.1, 0.3, 1, 3, 10, 30, and 100 mM). MTT assays were 
performed after the 2 cell lines were exposed to NaB for 72 hours. NaB was not cyto-
toxic or, at most, minimally cytotoxic at 1.0 mM. At NaB concentrations >1.0 mM, 
cell growth was significantly inhibited (Figure 2). Therefore, a NaB concentration of 
1.0 mM was used for all subsequent experiments.
When control cells and SW-1990 and JHP-1 cells treated with 1.0 mM NaB 
were examined by Western blot analysis, histone acetylation increased significantly 
in the SW-1990 and JHP-1 cells (Figure 3A). p53 and p21 expression in the 2 cell 
lines was detected by Western blotting after they were treated with 1 mM NaB for 
1, 2, and 4 hours. p53 and p21 expression was also apparent after NaB treatment 
(Figure 3B).
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Figure 2.  Cytotoxicity of sodium butyrate (NaB) to SW-1990 and JHP-1 cells. Each point 
represents the mean of triplicate analyses with SD. 
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Figure 3.  (A) Two pancreatic cancer cell lines were treated with 1 mM sodium butyrate 
(NaB) for 24 hours and the expression of acetylated histone H3 was examined 
by Western blot analysis. (B) Western blot of 53-kDa protein (p53) and p21. 
SW-1990 and JHP-1 cells were treated with 1 mM NaB for the indicated times 
prior to harvesting protein. ASU = arbitrary subunit.
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MTT assays were used to investigate whether the induction of p53 increased the 
cytotoxic effect of an anticancer drug on the pancreatic cell lines. Following treatment 
with NaB, the 50% inhibitory concentration (IC50) of cisplatin for SW-1990 cells was 
reduced to 0.012 μM from an IC50 of 0.02 μM for untreated cells. Similar results were 
obtained with fluorouracil and SN-38. However, sensitivity to paclitaxel was not in-
creased significantly by NaB treatment (Figure 4).
When SW-1990 cells were exposed to 0.01, 0.1, and 1 μM cisplatin, apoptosis was 
observed in NaB-treated cells exposed to 0.1 μM cisplatin (Figure 5). On the other 
hand, untreated SW-1990 cells had a low frequency of apoptosis, and were not signifi-
cantly affected by cisplatin, even at 0.1 μM.
DISCUSSION
In this study, p53 expression was not detected in 2 of 5 pancreatic cancer cell lines, 
SW-1990 and JHP-1. Functional p53 was induced in these cell lines by NaB treat-
ment. Furthermore, growth inhibition tests with various anticancer agents showed 
that drug sensitivity was significantly increased in these cell lines by NaB treat-
ment. These results suggest that enhancement of the effectiveness of anticancer 
drugs by p53 induction may be clinically useful for treating some cancers that have 
lost wild-type p53. Introduction of p53 was followed by induction of p21, suggest-
ing the ability of p53 to respond to DNA damage and enhanced cisplatin sensitivity 
manifested as DNA degradation.
Interestingly, although overexpression of p53 in cells treated with NaB affected 
their sensitivity to cisplatin, fluorouracil, and SN-38, their sensitivity to paclitaxel 
did not increase.42–45 In our DNA laddering study,46 a high frequency of apoptosis 
was observed in the NaB-treated cells compared with that of control cells. Mandal and 
Kumar47 reported that treating a human breast cancer cell line, MCF-7, with NaB 
induced apoptosis and growth inhibition (<2% without NaB; ~18% with NaB). This 
phenomenon is closely linked to the down-regulation of bcl-2 protein expression, and 
overexpression of bcl-2 in MCF-7 cells resulted in inhibition of apoptosis. Our results 
suggest that the same apoptosis pathway is present in pancreatic cell lines.
Future in vitro and experimental studies are needed to confirm these in vivo 
results.
CONCLUSIONS
This study found that NaB induced p53 expression in 2 pancreatic cancer cell lines 
(SW-1990 and JHP-1). Moreover, NaB acted on a biochemical modulator for anti- 
euplastic therapy. These phenomena may be helpful for finding a new approach for 
treating pancreatic cancers lacking functional p53 expression.
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Figure 4.  Sensitivity of SW-1990 cell lines to anticancer drugs with or without sodium 
butyrate (NaB) pretreatment. After NaB treatment, cells were treated with vari-
ous concentrations of cisplatin, fluorouracil, SN-38, and paclitaxel for 72 hours 
and cell viability was determined by MTT assay. Each point represents the mean 
of triplicate analyses with SD. IC50 = 50% inhibitory concentration. 
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